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Abstract 29 
 30 
Background 31 
The COVID-19 pandemic caused by SARS-CoV-2 remains a significant issue for global health, 32 
economics and society. A wealth of data has been generated since its emergence in December 2019 33 
and it is vital for clinicians to keep up with this data from across the world at a time of uncertainty and 34 
constantly evolving guidelines and clinical practice.    35 
 36 
Objectives 37 
Here we provide an update for clinicians on the recent developments about virology, diagnostics, 38 
clinical presentation, viral shedding, and treatment options for COVID-19 based on current literature.    39 
 40 
Sources 41 
We considered published peer-reviewed papers and non-peer-reviewed pre-print manuscripts on 42 
COVID19 and related aspects with an emphasis on clinical management aspects.  43 
 44 
Content 45 
We describe the virological characteristics of SARS-CoV-2 and clinical course of COVID-19 with an 46 
emphasis on diagnostic challenges, duration of viral shedding, severity markers and current treatment 47 
options.  48 
 49 
Implications 50 
The key challenge in managing COVID-19 remains the patient density. However, accurate diagnoses 51 
as well as early identification and management of high-risk severe cases are important for many 52 
clinicians. For improved management of cases, there is a need to understand test probability of 53 
serology, qRT-PCR and radiological testing, and the efficacy of available treatment options that could 54 
be used in severe cases with a high risk of mortality.  55 
Introduction 56 
The first cases of atypical pneumonia of unidentified aetiology were reported on December 30, 2019, 57 
from Wuhan, China. By January 7, 2020, a novel betacoronavirus, severe acute respiratory syndrome 58 
coronavirus (SARS-CoV-2) was identified, while the disease has been named COVID-19. COVID-19 59 
has now been declared a pandemic, affected nearly every country, with over 2.3 million confirmed 60 
cases and >160,000 deaths. The initial clinical case series from China largely comprised of 61 
hospitalised patients with severe pneumonia. Further data suggested that approximately 80% patients 62 
have mild disease, 20% require hospital admission, and approximately 5% require intensive care 63 
admission [1]. Mortality rates are higher among people over 60 years and with coexisting conditions; 64 
hypertension, diabetes and cardiovascular disease being the most common. Here we provide an 65 
update for clinicians on the recent developments about virology, diagnostics, clinical presentation, 66 
and treatment options for COVID-19 based on current literature.    67 
 68 
Virology  69 
Metagenomic sequencing and targeted real-time polymerase chain reaction (qRT-PCR) assays 70 
identified a novel human CoV (SARS-CoV-2) in bronchoalveolar lavage fluid taken from the initial 71 
patient cluster in Wuhan [2]. Infectious SARS-CoV-2 has been cultured on monkey Vero, human Huh7 72 
and primary human airway epithelial cells [3], where it is cytopathic. Furthermore, serum antibodies 73 
(IgM and IgG) from cases neutralized SARS-CoV-2 in cell culture and detected virus-infected cells by 74 
indirect immunofluorescence [3].  75 
 76 
Phylogenetic analysis reveals that SARS-CoV-2 is closely related to SARS-CoV (~80% similar) in the 77 
Sarbecovirus sub-family (genus Betacoronavirus) [2]. While an intermediate host has yet to be 78 
determined, it shares strong genetic similarity (>95%) to known bat coronaviruses from China, 79 
suggesting a likely bat origin. Relatively similar coronaviruses have been found in pangolins whose 80 
receptor-binding domain (RBD) of Spike (S) glycoprotein is more like to SARS-2-CoV-2 than known 81 
bat viruses [4].  82 
 83 
SARS-CoV-2 shares most of its gene content with SARS-CoV, including the S glycoprotein, the 84 
RNA-dependent RNA polymerase (Nsp12) and two proteases papain-like protease (PLpro) and 3C-85 
like protease (3CLpro) [3]. There is also substantial antigenic cross-reactivity between SARS-CoV-2 86 
and SARS-CoV [3, 5]. A recent study confirmed that the angiotensin-converting enzyme 2 (ACE2), 87 
expressed in the human respiratory tract epithelium, is the entry receptor for SARS-CoV-2 similar to 88 
SARS-CoV and has been shown to cause pneumonia in lab mice only expressing human ACE2 [6, 7]. 89 
This is likely mediated by the RBD of the S glycoprotein [8]. Although there is obvious homology 90 
between SARS-CoV and SARS-CoV-2, and cross neutralization has been observed [9],  significant 91 
biological differences, specifically in the S glycoprotein have been noted [5, 10, 11].  92 
 93 
Clinical presentation 94 
A key difference between COVID-19 and seasonal influenza-associated pneumonia is the potential 95 
severity of disease even in young adults without comorbidities [12]. In a study that compared three 96 
well-conducted Chinese case series to a reference group of patients with influenza-associated 97 
pneumonia from 73 German sentinel hospitals, the severity of pneumonia even in adults aged <60 98 
years without chronic preconditions was significantly greater in COVID-19. For instance, 28% of 99 
COVID-19 patients treated on the ICU had no reported comorbidity. The rate of ARDS and 100 
mechanical ventilation was markedly higher among COVID-19 patients. The median duration of 101 
ventilation was 9 days for non-invasive, and 17 days  for  invasive ventilation [12].  102 
 103 
Across all studies, the most common symptoms at onset of illness were fever, cough, fatigue, and 104 
myalgia. However, available data suggest that only half of patients are febrile at the time of admission 105 
[13, 14]. Gastrointestinal symptoms, including anorexia, nausea, vomiting and diarrhoea are also 106 
common, reported in nearly 40% patients in some cohorts [15, 16]. Furthermore, up to 10% patients 107 
present with gastrointestinal symptoms without respiratory symptoms or fever [17]. COVID-19 has 108 
been associated with a hypercoagulable state with increased risk of venous thromboembolism[18]. 109 
Neurological manifestations, including headache, dizziness, altered consciousness, ischaemic and 110 
haemorrhagic strokes, as well as muscle injury, have also been reported [19]. A third of patients 111 
reported taste or olfactory disorders in a small Italian cohort, including anosmia [20]. Other 112 
extrapulmonary manifestations include skin and ocular manifestations. An Italian study reported 113 
cutaneous manifestations in 20% patients [21]. Lastly, ocular manifestations consistent with 114 
conjunctivitis was reported in 32% COVID patients in a Chinese case series [22].   115 
 116 
The estimated mean incubation period is reported as 3-6 days (range 1.3-11.3) [12]. The duration 117 
from symptom onset to dyspnoea was 5-6 days [13, 17] On average, disease progresses further 118 
requiring hospitalisation at 7-8 days from symptom onset. Patients may initially appear relatively 119 
stable, but they often rapidly deteriorate with severe hypoxia [13, 17]. The key feature seen in these 120 
cases is acute respiratory distress syndrome (ARDS) [13, 17]. The interval from symptom onset to the 121 
development of ARDS is approximately 8-12 days [13]. In addition, the incidence of cardiovascular 122 
manifestations such as myocardial injury seems to be high, likely due to the systemic inflammatory 123 
response and immune system disorders during disease progression[23]. 124 
 125 
Illness severity and development of ARDS are associated with older age and underlying medical 126 
conditions [17]. Additionally, neutrophilia, raised lactate dehydrogenase and D-dimer, lymphocyte 127 
counts, CD3 and CD4 T-cell counts, AST, prealbumin, creatinine, glucose, low-density lipoprotein, 128 
serum ferritin, and prothrombin time were also associated with higher risk of severe disease and 129 
ARDS [17]. In a cohort of 191 patients with a definitive clinical outcome (137 discharged and 54 130 
died), mortality was independently associated with older age, higher qSOFA score, d-dimer >1 μg/mL 131 
on admission, and the majority had severe disease and experienced complications, such as ARDS, 132 
acute kidney injury, and sepsis [13]. Factors most associated with critical illness were admission 133 
oxygen saturation <88%, first d-dimer>2500, first ferritin >2500, and first CRP >200 [24]. 134 
Furthermore, patients with cardiovascular disease were shown to be more likely to develop severe 135 
symptoms[23] in keeping with picture seen in MERS-CoV and SARS.  136 
 137 
In comparison, most children appear to have mild disease. Among 1391 asymptomatic and 138 
symptomatic children (median age: 6.7 years) with known COVID19 contact in Wuhan Children’s 139 
Hospital [25], 171 (12.3%) were SARS-CoV2-positive; 27 (15.8%) had no symptoms or radiologic 140 
features of pneumonia, 33 (19.3%) had upper respiratory symptoms, and 64.9% had pneumonia. 141 
Three patients (with coexisting conditions) required intensive care and 1 death.  142 
 143 
In terms of co-infections, a pre-print examining >8000 samples of COVID-19 contacts tested for 144 
SARS-CoV2 in China reported viral co-infections in 5.8% of COVID-19 positive individuals 145 
(including seasonal coronaviruses, influenza A virus and rhinoviruses [26]. Another study of 1206 146 
patients identified viral co-infection in 24 of 116 (21%) SARS-CoV2-positive patients; 147 
rhino/enterovirus, respiratory syncytial virus, and seasonal CoVs were most common [27]. Bacterial 148 
and fungal co-infections with SARS-CoV-2 have been documented especially in the ICU setting, 149 
including Acinetobacter baumanii and Klebsiella pneumoniae [28]. Among 191 patients, non-150 
survivors were more likely to have sepsis based on qSOFA score and secondary infection, although 151 
detailed bacteriology results were not reported [13]. Secondary infection and positive association 152 
between steroid administration and secondary infection should be explored further.  153 
 154 
Molecular and Serological Diagnosis 155 
The first genome sequence for SARS-CoV-2 was released on virological.org on 10 January (GenBank 156 
accession number MN908947). This allowed the rapid development of several sensitive and specific 157 
qRT-PCR assays [29]. Many laboratories worldwide are now able to test for SARS-CoV-2. Assays 158 
have been described that detect <10 copies of SARS-CoV-2 per reaction and will not cross-react with 159 
SARS-CoV or other human coronaviruses [29]. However, sensitivity and specificity of these tests 160 
remain unknown and there is no clear consensus on which is preferred.  161 
 162 
Viral RNA loads by qRT-PCR were substantially higher in sputum compared to throat swabs [3, 30, 163 
31], suggesting that the type of sample may also influence the outcome of the test. Therefore, 164 
currently submission of both lower and upper respiratory tracts samples is advised.  165 
 166 
Precise molecular detection is hampered by the variability in viral loads in the upper respiratory tract, 167 
especially at later stages of infection. In a study from China, among 241 COVID-19 patients with at 168 
least one positive SARS-CoV-2 qRT-PCR test result, in the first test, 384 (63.0%) were negative [32]. 169 
In addition, several tests at different points were variable from the same patients during the course of 170 
diagnosis and treatment.[32]. Therefore, a single positive test should be confirmed by a second qRT-171 
PCR assay targeting a different SARS-CoV-2 gene. Although, similar studies in Taiwan and Hong 172 
Kong reported less false-negatives[33]. Secondly, a single negative SARS-CoV-2 test (especially if 173 
from upper respiratory tract specimen) or a positive test result for another respiratory pathogen result 174 
should not be used to exclude COVID-19 infection. These findings indicate that qRT-PCR has low 175 
probability of ruling out an infection and in clinically high suspicious cases repeat sampling and also 176 
CT images may need to be used to guide the diagnosis. 177 
 178 
Antibody-based methods to detect seroconversion in serum or plasma based upon enzyme-linked 179 
immunosorbent assays (ELISA), indirect-immunofluorescence or virus neutralisation have been 180 
reported  [34-36]. Around 40-50% patients develop an antibody response to SARS-CoV-2 infection 181 
after 7 days, and the majority by 14 days [35, 37]. S1 has been shown to be more specific than S as an 182 
antigen for SARS-CoV-2 in serological diagnosis [36]. The commercial S1 IgG and IgA assays have 183 
lower specificity but IgA showing higher sensitivity [36]. Recently, an ELISA assay based on 184 
detection of recombinant S protein by serum antibodies demonstrated robust and scalable 185 
determination of seroconversion that will facilitate screening of potential exposed individuals for 186 
evidence of past infection [38]. Since seroconversion occurs relatively late in infection, rapid antibody 187 
tests have a limited role in the diagnosis of acute infection; qRT-PCR remains the ‘gold standard’.   188 
 189 
There is an ongoing work to understand protective antibody level and immunological marker. Among 190 
175 recovered laboratory-confirmed COVID-19 patients, neutralizing antibodies (NAb) peaked at 10 191 
to 15 days after disease onset. However, approximately 30% failed to develop good level of NAb 192 
titres (ID50: < 500)[39]. In addition, patients who did not generate NAbs at the time of discharge did 193 
not develop NAbs thereafter. These results highlight that some patients with SARS-CoV-2 would 194 
recover without developing high titers of virus-specific NAbs. These findings have some implications 195 
for vaccine development and also for convalescent plasma treatment as the donor plasma should be 196 
titrated before use in passive therapy. There is less information available on the T cell response during 197 
SARS-CoV-2 infection and how it correlates with the NAb titres.  198 
 199 
Duration of viral shedding and isolation period 200 
SARS-CoV-2 RNA has been identified by qRT-PCR in respiratory tract samples 1-2 days prior to 201 
symptom onset and can persist for 7-12 days in moderate cases, and up to 2 weeks in severe cases [35, 202 
40]. SARS-CoV-2 has also been detected in whole blood [41], saliva [42], faeces [43], and urine [44] 203 
by qRT-PCR (Table 1).. In several case series with serial sampling, viral loads were highest soon after 204 
symptom onset [35, 45]. Patients with severe COVID-19 had significantly higher viral load and 205 
longer period of viral shedding than mild cases [46]. Prolonged viral RNA shedding has been reported 206 
from throat swabs up to 37 days among adult patients [13], and in faeces, for over one month after 207 
illness onset in children[40, 47]. However, detection of viral RNA by qRT-PCR does not necessarily 208 
equate with infectious virus. No live virus was cultured from 9 mild COVID-19 cases beyond day 8 209 
after symptom onset in throat swabs or sputum despite ongoing high viral load [35]. Persistently high 210 
levels of RNA were also identified in the stool of the mild cases, but no live virus was cultured [35]. 211 
These findings suggest that patients may continue to shed RNA in various samples for a long period, 212 
but this does not equate to infectiousness potential (Table 1). This supports the current guidance of 7-213 
14 days self-isolation from symptom onset. Certain hospitals following a protocol to confirm viral 214 
clearance prior to transfer out of dedicated COVID-19 wards, however, this may not be required 215 
given the prolonged RNA shedding without the evidence of viable virus. However, whether faecal-216 
oral or faecal-respiratory transmission occurs, and the role of shedding in severe cases in transmission 217 
requires further exploration.  218 
 219 
Transmission patterns 220 
A review of modelling studies based on Chinese case numbers report a median basic reproduction 221 
number (R0) of 2.79 [48], though R0 as high as 5.7 have been reported [49].These estimates are 222 
substantially higher than the reproduction number for seasonal influenza (~1.3) [50], and indicate that 223 
control measures would need to prevent >60% transmission to stop the epidemic. Of note, R0 will 224 
vary by setting, and can be substantially reduced by countermeasures, as have been observed in China 225 
[51].  226 
It is now clear that a significant proportion of individuals with COVID-19 have very mild or no 227 
symptoms. Asymptomatic infection at the time of laboratory testing have been reported [52, 53], 228 
though a large proportion go on to develop symptoms. For instance, among 55 asymptomatic carriers 229 
with positive qRT-PCR for SARS-CoV-2 in pharyngeal swab samples, 14 went on to develop mild, 230 
39 ordinary, and 2 severe COVID-19 [54]. There have been several reports of SARS-CoV-2 231 
transmission from asymptomatic or presymptomatic persons [55, 56], which poses significant 232 
challenges to contact tracing. Nevertheless, the relative contribution of asymptomatic or pre-233 
symptomatic transmission on the overall transmission dynamics of the pandemic remains uncertain. 234 
Thus, household studies to study secondary human transmission of SARS-CoV-2 and serosurveys to 235 
determine the incidence of asymptomatic and subclinical infections are needed. 236 
 237 
A further consideration is superspreading events, whereby a small number of cases are responsible for 238 
a disproportionate number of secondary cases. This was a feature of both SARS- and MERS-CoV, 239 
responsible for multiple nosocomial outbreaks [57, 58]. Several superspreading events has been 240 
reported for COVID-19 [17]. Rapid identification and mitigation of these events will be crucial to 241 
controlling this pandemic.  242 
 243 
Treatment options in clinical trials 244 
At present, there are no approved antivirals for SARS-CoV-2. Several antivirals that have shown 245 
promise against SARS- or MERS-CoV in vitro and in vivo are currently being evaluated in clinical 246 
trials for COVID-19. Lopinavir/ritonavir (LPV/r), a protease inhibitor used as an antiretroviral, 247 
showed inconclusive findings for the treatment of SARS, but demonstrated strong in vitro and in vivo 248 
antiviral activity against MERS-CoV when combined with interferon-beta (IFNb) [59]. The first of a 249 
number of clinical trials involving LPV/r was recently published [60]. Among 199 seriously ill 250 
laboratory-confirmed COVID-19 patients, no significant difference in clinical improvement, mortality 251 
or viral clearance was observed between LPV/r (n=99) and standard care (n=100) arms. However, 252 
treatment was instituted late in infection; median time from symptom onset to treatment was 13 days, 253 
and >40% of patients had undetectable viral load before or during treatment. The results were 254 
complicated by the variable use of other treatments, including interferon, glucocorticoids and 255 
antibiotics. Of note, day 28 mortality was lower (not significantly) in those with early treatment (19% 256 
vs. 27%) and those who received LPV/r also had lower vasopressor and non-invasive ventilation use.  257 
Another promising drug is remdesivir, a novel nucleotide analogue that interferes with nsp12 258 
polymerase [61]. It has shown in vitro activity against a wide range of RNA viruses including SARS 259 
and MERS-CoV [62, 63], and has also demonstrated superior antiviral activity compared to LPV/r-260 
IFNb against MERS-CoV in a mouse model [59]. Against SARS-CoV-2, it has shown promising 261 
antiviral activity in Vero E6 cells and Huh7 cells [64]. Remdesivir has been given to a small number 262 
of patients with severe COVID-19 through compassionate use, however, given the lack of 263 
randomisation and control group interpretation of the findings is difficult [65]. There are ongoing 264 
RCTs assessing its efficacy and safety in patients with COVID-19 worldwide, and a study in France 265 
evaluating its impact on viral shedding in high and moderate risk contacts in confirmed COVID-19 266 
cases (NCT04259892).  267 
 268 
Other candidate antivirals are studied in RCTs, including favipiravir and hydroxychloroquine, which 269 
has been shown to inhibit virus cell entry in vitro [66]. Hydroxychloroquine (HCQ), an analogue of 270 
chloroquine, has demonstrated anti-SARS-CoV-2 activity in vitro [67]. Among a small open-label 271 
non-randomised study, patients treated with HCQ and HCQ + Azithromycin showed viral load 272 
reduction compared to controls. However, there has been significant concerns and ethical issues about 273 
the content, the ethical approval of the trial and the peer review process prior to publication raised by 274 
several physicians and also the International Society of Antimicrobial Chemotherapy.  In a small RCT 275 
of HCQ (n=30), there was no change in viral load or clinical outcome after 7 days [68]. Currently, 276 
there are 45 trials evaluating chloroquine or HCQ for the treatment and prophylaxis of COVID-19, 277 
including multi-centre RCTs in the UK (RECOVERY, ISRCTN50189673), Europe (DisCoVeRy, 278 
NCT04315948) and also globally involving >70 countries (SOLIDARITY, ISRCTN83971151). 279 
 280 
Host-targeted therapeutic options are also being explored, such as inhibition of human cytokine 281 
interleukin-6 (IL-6), the abundance of which has been associated with worse prognosis [69]. A 282 
preprint including 21 patients that received Tocilizumab (an IL-6 receptor inhibitor) reported 283 
improvement in symptoms, hypoxaemia and CT changes in the majority of patients[70]. There are 284 
ongoing RCTs evaluating tocilizumab and sarilumab, also an IL-6 receptor inhibitor. With insufficient 285 
evidence of efficacy for any existing treatments, the IDSA recommends that experimental therapies 286 
should only be offered to patients in the context of a clinical trial [71].  287 
 288 
There is no licenced vaccine to protect against COVID-19. However, a number of experimental 289 
candidates are in development with some already in early clinical trials. Most vaccine candidates 290 
focus on immunisation with only the S glycoprotein, which is the major target for neutralization 291 
antibodies. Candidate vaccines differ in the mode of S delivery and platforms dependent on 292 
recombinant protein, mRNA or viral vectored approaches are being tested. Passive immunisation 293 
through transfusion of convalescent sera or plasma containing neutralizing antibodies from recovered 294 
donors have been reported in several case series, with clinical improvement reported in recipients [72, 295 
73]. Clinical trials evaluating convalescent plasma as treatment for severe COVID-19 are ongoing. 296 
 297 
Conclusion 298 
A wealth of data has been generated already on COVID-19 since early January 2020. Nevertheless, 299 
key questions remain regarding understanding the population at risk and age groups, proportion of 300 
individuals that have had asymptomatic infections and their transmission potential, endemicity and 301 
seasonality of COVID-19, and whether stringent physical distancing measures will be effective in 302 
countries outside China. The main challenge in managing COVID19 remains the patient density, 303 
however, accurate diagnoses as well as early identification and management of high-risk severe cases 304 
remains a daily battle for many clinicians. For improved management of cases, there is a need to 305 
understand test probability of serology, qRT-PCR and radiological testing, and the efficacy of 306 
available treatment options that could be used in severe cases with high risk of mortality.  307 
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